retatrutide type 2 diabetes trial results 2024 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a retatrutide type 2 diabetes phase

In February 2024, Lars Fruergaard Jrgensen, the CEO of Ozempic maker Novo Nordisk, said he was fielding calls from scared food-company executives about the impact of the drug on the industry

If you are concerned about discontinuation effects, understanding withdrawal symptoms from GLP-1 agonists helps you plan for the possibility that you might need to stop tirzepatide at some point while continuing bupropion

number needed to treat = 48

What the evidence does and does not show Growth hormone pathways reliably increase lean body mass

2013 2 2 , HbA 1c 6,9-9,2%, -0,79% ( ) -0,61% ( ) (Vasilakou, 2013)

PPAR agonist fenofibrate enhances fatty acid -oxidation and attenuates polycystic kidney and liver disease in mice